Recap the 4 late-breaking phase 3 trials from ESMO 2026 Presidential Symposium I in melanoma, bladder cancer, small cell lung cancer, and prostate cancer.
|Videos|June 14, 2016
Phase III COMBI-d Study of Dabrafenib and Trametinib in Patients With Melanoma
Author(s)Keith T. Flaherty, MD
Keith T. Flaherty, MD, provides an overview of the phase III COMBI-d study, which examined the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) as a treatment of patients with BRAF-mutant metastatic melanoma.
Advertisement
Advertisement
Related to this article
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Findings highlight the need for individualized monitoring after discharge, despite low rates of severe toxicities.
ESMO 2026 Presidential Symposium III: ADC and immunotherapy highlights from the the ARTEMIS-011, TroFuse-005, KEYNOTE-C93, and MOIO trials.
ESMO 2026 unveils GI cancer advances: targeted and immunotherapy regimens boost survival in pancreatic, colorectal, gastric, and HER2+ gastroesophageal disease.
ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The guidelines incorporate cosibelimab for locally advanced cutaneous squamous cell carcinoma after favorable results in the CK-301-101 trial.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
2
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
3
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5